Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alexander Spira

Showing results (1-10 of 83) with videos related to

Pageof 9
Sort By:
Seminars in Surgical Oncology|September 26, 2003
Extensive-stage small-cell lung cancerAlexander Spira, David S Ettinger
Methods in Molecular Biology (Clifton, N.J.)|November 15, 2011
Clinical trial design in the age of molecular profilingAlexander Spira, Kirsten H Edmiston
Expert Opinion on Biological Therapy|June 14, 2025
An evaluation of datopotamab deruxtecan for the treatment of non-small cell lung cancerNeel Belani, Anjali Donnelly, Alexander Spira
Journal of the Advanced Practitioner in Oncology|August 1, 2022
Improving Cancer Care Delivery: Learnings for Oncology Nurses and Patient Navigation From a National Quality SurveyJennifer Aversano, Leigh M Boehmer, Alexander Spira
Thoracic Cancer|May 24, 2021
Clinical outcomes and resource utilization after surgical resection with curative intent among patients with non-small cell lung cancer treated with adjuvant therapies in a community oncology setting: A real-world retrospective observational studyBeilei Cai, Nicole Fulcher, Marley Boyd, et al.
Future Oncology (London, England)|May 3, 2023
Adagrasib: a novel inhibitor for <i>KRAS</i>-mutated non-small-cell lung cancerMatthew Z Guo, Kristen A Marrone, Alexander Spira, et al.
Methods in Molecular Biology (Clifton, N.J.)|May 15, 2017
Innovations in Clinical Trial Design in the Era of Molecular ProfilingJulia D Wulfkuhle, Alexander Spira, Kirsten H Edmiston, et al.
Cancer Medicine|June 12, 2023
Real-world outcomes among patients with EGFR-mutated non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors versus immunotherapy or chemotherapy in the first-line settingJon Apple, Rahul Shenolikar, Kevin De Silva, et al.
Cancer Journal (Sudbury, Mass.)|December 14, 2021
Poly(ADP-Ribose) Polymerase Inhibition in Small Cell Lung Cancer: A ReviewMatthew Z Guo, Kristen A Marrone, Alexander Spira, et al.
Expert Opinion on Biological Therapy|March 25, 2017
Prospects and progress of atezolizumab in non-small cell lung cancerJohan Vansteenkiste, Els Wauters, Keunchil Park, et al.
Pageof 9

Showing results (1-10 of 83) with videos related to

Sort By:
Pageof 9
Seminars in Surgical Oncology|September 26, 2003
Extensive-stage small-cell lung cancerAlexander Spira, David S Ettinger
Methods in Molecular Biology (Clifton, N.J.)|November 15, 2011
Clinical trial design in the age of molecular profilingAlexander Spira, Kirsten H Edmiston
Expert Opinion on Biological Therapy|June 14, 2025
An evaluation of datopotamab deruxtecan for the treatment of non-small cell lung cancerNeel Belani, Anjali Donnelly, Alexander Spira
Journal of the Advanced Practitioner in Oncology|August 1, 2022
Improving Cancer Care Delivery: Learnings for Oncology Nurses and Patient Navigation From a National Quality SurveyJennifer Aversano, Leigh M Boehmer, Alexander Spira
Thoracic Cancer|May 24, 2021
Clinical outcomes and resource utilization after surgical resection with curative intent among patients with non-small cell lung cancer treated with adjuvant therapies in a community oncology setting: A real-world retrospective observational studyBeilei Cai, Nicole Fulcher, Marley Boyd, et al.
Future Oncology (London, England)|May 3, 2023
Adagrasib: a novel inhibitor for <i>KRAS</i>-mutated non-small-cell lung cancerMatthew Z Guo, Kristen A Marrone, Alexander Spira, et al.
Methods in Molecular Biology (Clifton, N.J.)|May 15, 2017
Innovations in Clinical Trial Design in the Era of Molecular ProfilingJulia D Wulfkuhle, Alexander Spira, Kirsten H Edmiston, et al.
Cancer Medicine|June 12, 2023
Real-world outcomes among patients with EGFR-mutated non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors versus immunotherapy or chemotherapy in the first-line settingJon Apple, Rahul Shenolikar, Kevin De Silva, et al.
Cancer Journal (Sudbury, Mass.)|December 14, 2021
Poly(ADP-Ribose) Polymerase Inhibition in Small Cell Lung Cancer: A ReviewMatthew Z Guo, Kristen A Marrone, Alexander Spira, et al.
Expert Opinion on Biological Therapy|March 25, 2017
Prospects and progress of atezolizumab in non-small cell lung cancerJohan Vansteenkiste, Els Wauters, Keunchil Park, et al.
Pageof 9